Form 8-K - Current report:
SEC Accession No. 0001193125-26-266770
Filing Date
2026-06-11
Accepted
2026-06-11 09:00:07
Documents
17
Period of Report
2026-06-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d570985d8k.htm   iXBRL 8-K 73548
2 EX-3.1 d570985dex31.htm EX-3.1 165994
3 EX-4.1 d570985dex41.htm EX-4.1 78583
4 EX-10.1 d570985dex101.htm EX-10.1 365164
5 EX-10.2 d570985dex102.htm EX-10.2 76439
6 EX-10.3 d570985dex103.htm EX-10.3 285987
7 EX-10.4 d570985dex104.htm EX-10.4 78354
  Complete submission text file 0001193125-26-266770.txt   1518907

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA jagx-20260608.xsd EX-101.SCH 3205
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20260608_lab.xml EX-101.LAB 18738
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20260608_pre.xml EX-101.PRE 11724
20 EXTRACTED XBRL INSTANCE DOCUMENT d570985d8k_htm.xml XML 3843
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 261081577
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)